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Infective endocarditis is a microbial infection of the endothelial surface of the heart, predominantly the heart 
valves, that is associated with high mortality and morbidity. Few contemporary data exist regarding affected 
children in our context. 
 
Aims and Objectives: We aimed to describe the profile and treatment outcomes of infant and childhood 
endocarditis at our facilities. 
 
Methods: This is a retrospective review of infants and children with endocarditis at two public-sector 
hospitals in the Western Cape Province of South Africa over a 5-year period. Patients with “definite” and 
“possible” endocarditis according to Modified Duke Criteria were included in the review.  
 
Results:  Forty-nine patients were identified for inclusion; 64% of patients met “definite” and 36% “possible” 
criteria. The in-hospital mortality rate was 20%; 53% of patients underwent surgery with a post-operative 
mortality rate of 7.7%. The median interval from diagnosis to surgery was 20 days (interquartile range 9-47 
days). Valve replacement occurred in 28% and valve repair in 58%. There was a significant reduction in 
valvular dysfunction in patients undergoing surgery and only a marginal improvement in patients treated 
medically. Overall, 43% of patients had some degree of residual valvular dysfunction. 
 
Conclusion:  Endocarditis is a serious disease with a high in-hospital mortality and presents challenges in 
making an accurate diagnosis. Despite a significant reduction in valvular dysfunction, a portion of patients 
had residual valvular dysfunction. Early surgery is associated with a lower mortality rate, but a higher rate 
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Infective endocarditis (IE), defined as a microbial infection of the endothelial surface of the heart, is 
relatively rare in children.1, 2 It is, however, associated with substantial morbidity and mortality. The most 
frequent sites involved in endocarditis are the heart valves (native or prosthetic), but it may occur 
elsewhere on the endocardium such as septal defects, mural endocardium or foreign bodies (intracardiac 
patches and surgically constructed shunts).1 
 
 Epidemiological studies of infective endocarditis in paediatric populations in developing countries have 
demonstrated that congenital heart disease (CHD) and rheumatic heart disease (RHD) are the most 
significant risk factors for developing IE in these patients. Between 39% and 53%4 of children have RHD 
as their underlying condition and approximately 45%3, 4 of children had CHD as their underlying condition. 
There are numerous bacteria responsible for causing infective endocarditis5, however Viridans group 
streptococci and Staphylococcus aureus have been identified in studies from both developed countries 
and developing countries as being the most common organisms responsible in children 3, 4, 6. 
 
In the so-called ‘surgical era’, there are increasing numbers of hospital-acquired organisms such as 
coagulase negative staphylococci (CoNS), gram-negative bacilli, and yeasts that cause IE.7 In developing 
countries with less availability of congenital heart surgery this may not be the case, and it is expected that 
community-acquired IE is the predominant type of IE in those countries.  
 
Catheter-related IE in children and neonates is also a known association. IE may occur in infants and 
children with no predisposing8 cardiac conditions, especially in staphylococcus aureus septicemia.9 
 
There appears to be conflicting evidence with regards to the effect that Human Immunodeficiency Virus 
(HIV) infection has on the risk of developing IE. In a prospective study of IE in SA, HIV was not associated 
with an increased risk for IE in adult patients.10 However in a multi –centre autopsy study of patients with 
HIV, it was found that the prevalence of HIV in IE was similar to that in other high-risk groups such as 
intravenous drug users11. It has also been found that patients with advanced HIV disease have a 30% 
higher mortality with IE than asymptomatic HIV infected patients12.The high prevalence of HIV infection 
and RHD in South Africa however, may result in a significant number of patients with IE to be 
coincidentally HIV infected.13 To our knowledge no work has been published on relationship between HIV 
and IE in children.  
 
Bacteria originating from the mouth account for a significant proportion of cases of IE and poor oral 
hygiene is an important risk factor for  IE in patients with predisposing conditions14. A transient bacteremia 
may occur in patients following dental procedures as well as during routine oral activities such as tooth 
brushing, flushing and chewing, especially in patients with poor oral hygiene placing these patients at an 
 
increased risk of developing IE.14 It has therefore been a long standing practice to give antibiotic 
prophylaxis to patients with CHD undergoing dental procedures. However in 2008 in the United Kingdom 
the National Institute for Health and Clinical Excellence (NICE) guidelines were published stating that 
antibiotic prophylaxis before any invasive procedure should cease and should only be given at the 
patient’s request15 The American Heart Association (AHA) stated in their guidelines that it is reasonable to 
shift a disproportionately large focus on antibiotics prophylaxis to an emphasis on oral hygiene and 
prevention of oral disease5 Because of the high prevalence of RHD and poor oral hygiene in SA and other 
developing countries, the SA Heart association has not adopted the UK guidelines or the AHA guidelines 
but recommends the use of antibiotic prophylaxis in patients undergoing dental procedures who have 
cardiac lesions that are considered a high risk for the development of IE14. The Western Cape Paediatric 
Cardiology Service in conjunction with the Dental Departments at Red Cross Children’s Hospital and 
Tygerberg Hospital adhere to the guidelines established by the SA Heart association for the prevention of 
IE in children undergoing dental procedures.  
 
The diagnosis of IE is based on modified Duke’s criteria which classifies IE into 3 groups: definite, 
possible and those in whom the diagnosis is rejected according to major and minor criteria.16  
 
Transthoracic echocardiography (TTE) has a sensitivity of up to 97% in the detection of IE in children and 
thus plays a central role in its diagnosis and management.17 The site and size of the lesion, valvular and 
cardiac function as well as periannular extension of the vegetation can be detected by 
echocardiography.18 
 
Guidelines, based predominantly on expert opinion and case series, exist for the indications and timing of 
surgery in the management of IE in adults.19 Recommendations regarding the management of IE in infants 
and children are extrapolated from the adult guidelines along with a limited number of case series and 
expert consensus.5 These indications for surgery are determined by: the size and location of the 
vegetations (> 10mm, left sided lesions), presence of systemic emboli, progression of heart failure and the 
presence of abscesses and fistula within the heart.5, 18 
 
Early surgical intervention in the management of childhood and infant IE, defined as surgery within 7 days 
of diagnosis, has been shown to be beneficial and safe when indicated. In a retrospective review of the 
surgical management of children with IE over a 15-year period at Texas Children’s Hospital, 61% of 
patients underwent surgery within 7 days of diagnosis (25% within the first 3 days after diagnosis). The 
authors concluded that early surgical therapy had a low risk of septic embolisation, recurrence and 
operative mortality with high rates of successful valve repair.20 
 
 Medical management of IE consists of a prolonged course of intravenous antibiotics.21 The choice of 
antibiotics and duration of treatment is determined by  microbiological cultures of the patient’s blood or 
directly from samples of the vegetation in patients who undergo surgery.5 The use of central venous 
catheters in the care of newborns has led to an increase in the incidence of IE in neonates with structurally 
 
normal hearts5, and the prevention of sepsis is therefore an important tool for the prevention of IE in these 
patients. Strict adherence to aseptic techniques when inserting and using central venous catheters 
reduces the frequency of catheter-related infections22 
 
A systematic review of the global and regional burden of IE over a 20-year period (1990 – 2010) for all 
age groups found that 15.8% of patients with IE had strokes, 32.4% underwent valvular surgery and the 
overall case fatality rate was 21%. In this review, however no studies were identified that reported on the 
incidence and burden of the disease in Sub-Saharan Africa.23 A 3-year prospective epidemiological study 
of IE in the Western Cape looking at patient characteristics, sequelae, morbidity and mortality was 
conducted at Tygerberg Hospital between 1997 and 2000. The study focused on adult IE, with the mean 
age of participants being 37.7 years. The 6-month mortality rate was 35% and the predominant underlying 
condition was RHD, occurring in approximately 76.6% of patients with IE. 10  
 
The outcomes of infants and children with IE managed in the Western Cape Paediatric Cardiology 
Service, as well as the impact of this disease in terms of long- term morbidity and mortality in affected 
children is less well described. The paucity of data pertaining to IE in children in the developing world 
makes decision-making regarding the optimal treatment of IE in children challenging. There is also a lack 
of evidence guiding the optimal timing of surgical intervention. 
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1.2 Ethical Considerations 
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Journal's mission. Prospective authors are encouraged to consult with the editors and members of 
the Editorial Board with any inquiries. The editors encourage the submission of articles from 
developing countries. 
 
Articles should be concerned with original research not published previously and not being 
considered for publication elsewhere. Authors must ensure that their studies comply with 
appropriate institutional and national guidelines for ethical matters. Specifically, by submission of 
a manuscript, the authors are responsible for compliance with guidelines and regulations of the 
authors' institution and all appropriate governmental agencies. 
 
Articles including human subjects must include a statement that informed consent was obtained 
and that the study was reviewed and approved by the institution's committee on human 
experimentation. Articles including animal experimentation must conform to the principles of the 
American Physiological Society, and a statement acknowledging conformation to these standards 
must be included in the Materials and methods section of the manuscript. Authors are also 
requested to identify possible conflicts of interest, especially if they relate to commercial 




The policy of Cardiology in the Young is that authors (or in some cases their employers) retain 
copyright and grant Cambridge University Press a licence to publish their work. In the case of gold 
open access articles this is a non-exclusive licence. Authors must complete and return an author 
publishing agreement form as soon as their article has been accepted for publication; the journal 
is unable to publish the article without this. Please download the appropriate publishing 
agreement here. 
 
For open access articles, the form also sets out the Creative Commons licence under which the 
article is made available to end users: a fundamental principle of open access is that content 
should not simply be accessible but should also be freely re-usable. Articles will be published 
under a Creative Commons Attribution license (CC-BY) by default. This means that the article is 
freely available to read, copy and redistribute, and can also be adapted (users can “remix, 
transform, and build upon” the work) for any commercial or non-commercial purpose, as long as 
proper attribution is given. Authors can, in the publishing agreement form, choose a different 
kind of Creative Commons license (including those prohibiting non-commercial and derivative use) 
if they prefer. 
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Abstract
Infective endocarditis is a microbial infection of the endothelial surface of the heart, predomi-
nantly the heart valves, that is associated with highmortality andmorbidity. Few contemporary
data exist regarding affected children in our context.
Aims and Objectives: We aimed to describe the profile and treatment outcomes of infant and
childhood endocarditis at our facilities.Methods: This is a retrospective analysis of infants and
children with endocarditis at two public sector hospitals in theWestern Cape Province of South
Africa over a 5-year period. Patients with “definite” and “possible” endocarditis according to
Modified Duke Criteria were included in the review. Results: Forty-nine patients were identified
for inclusion; 29 had congenital heart disease as a predisposing condition; 64% of patients met
“definite” and 36% “possible” criteria. The in-hospital mortality rate was 20%; 53% of patients
underwent surgery with a post-operative mortality rate of 7.7%. The median interval from
diagnosis to surgery was 20 days (interquartile range, 9–47 days). Valve replacement occurred
in 28% and valve repair in 58%. There was a significant reduction in valvular dysfunction in
patients undergoing surgery and only a marginal improvement in patients treated medically.
Overall, 43% of patients had some degree of residual valvular dysfunction. Conclusion:
Endocarditis is a serious disease with a high in-hospital mortality and presents challenges in
making an accurate diagnosis. Despite a significant reduction in valvular dysfunction, a portion
of patients had residual valvular dysfunction. Early surgery is associated with a lower mortality
rate, but a higher rate of valve replacement compared with delayed surgery.
Infective endocarditis is a microbial infection of the endothelial surface of the heart, predomi-
nantly the heart valves, that is associated with high mortality and morbidity.1 It typically occurs
when bacteria, or other microorganisms, enter the bloodstream in patients with abnormal or
denuded endothelium.
Congenital heart disease (CHD) and rheumatic heart disease (RHD) are the main predispos-
ing cardiac conditions in children with endocarditis in low- and middle-income countries.2
Central indwelling catheters, through their ability to introduce bacteria into the blood stream
and potential to cause endocardial erosion, is also a risk factor.3 Endocarditis has also been
identified in patients with no predisposing cardiac conditions, particularly in association with
Staphylococcus aureus bacteraemia.4
The diagnosis of endocarditis is approached as a syndrome using theModified Duke Criteria
that classifies it as “definite”, “possible” and “rejected” according to major and minor clinical
criteria.3 In an analysis of 100 consecutive patients in the Duke University database with
“definite” endocarditis according to pathological criteria, 76 had clinical criteria for “definite”
endocarditis and 24 had clinical criteria for “possible” endocarditis, while none had criteria for
“rejected” endocarditis.5
Surgery is an important part of the management of these patients. Achieving a low mortality
rate, a low embolic rate and no residual valvular dysfunction is the ideal outcome. There was
a significant reduction in mortality and systemic embolisation in adult patients who had early
surgery compared with delayed surgery in The Early Surgery versus Conventional Treatment
for Infective Endocarditis (EASE) study.6 Findings from a retrospective review of the surgical
management of children at Texas Children’s Hospital were that early surgery is associated with
a low risk of embolisation, recurrence and operative mortality.7
At our facility we follow the 2002 and updated 2015 American Heart Association guidelines
for the management of endocarditis in children.1,3 However, in the absence of clinical trials in
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children, these recommendations are based on case series and
expert opinion, with low levels of scientific evidence.3 In patients
who are surgically managed for valvular endocarditis, it is our
policy to achieve valve repairs as far as possible. The decision to
replace or repair a valve is made at the time of surgery based on
the viability of the valve. Outcomes of the management of these
children in our settings are not known, making it difficult to assess
the treatment strategies used and optimise the management of this
complex disorder. We therefore aimed to describe the profile of
infants and children with infective endocarditis at our facility
and assess their outcomes to assist in optimal decision-making.
Methods
Study population
A retrospective chart review of children, from birth to 14 years of
age, diagnosed with endocarditis at Red Cross War Memorial
Children’s and Tygerberg Hospitals in Cape Town, South
Africa, from January 2013 to December 2017 was conducted.
These two tertiary-level government hospitals serve the public
sector of the Western Cape Province of South Africa.
Patients were identified through a search of the paediatric
cardiology unit database using the search terms “Infective
Endocarditis, Endocarditis and Vegetation”. This was augmented
with cross-referencing echocardiograms, ward and surgery record
books, and a search of discharge summaries using the relevant
ICD-10 code (I33.0). Each case was classified using the
Modified Duke Criteria. Patients meeting criteria for “possible”
endocarditis (without a suitable alternate diagnosis) and “definite”
endocarditis were included for analysis. Patients meeting criteria
for “rejected” endocarditis were excluded. Information was entered
and stored on the University of Cape Town-supported research
electronic data capture (REDCap) database.
Demographic details and basic patient characteristics, includ-
ing human immunodeficiency virus status, were entered into the
database. Echocardiographic findings prior to and after the com-
pletion of treatment were recorded. We used the most recent
American Heart Association/American College of Cardiology
classification to quantify valve regurgitation or stenosis as mild,
moderate or severe in standardised echo reports.8 The causative
organism, if identified, was recorded. Complications and embolic
phenomena were described. The type of intervention performed
(medical and surgical), the time interval from diagnosis until
surgery as well as the type of surgical intervention were noted.
Statistical analysis
Data were analysed using Stata 14.2 (StataCorp, Texas, United
States of America). Continuous variables have been expressed as
medians with interquartile ranges, and categorical variables are
expressed as absolute number frequencies and percentages. The
change in classification of valvular dysfunction from pre- to
post-treatment was analysed using the McNemars-Bowker test
of symmetry.9
Results
Over a 5-year period from January 2013 to December 2017, 49 new
cases of infant and childhood endocarditis were identified, the
equivalent of approximately one new case every 5–6 weeks.
Patient characteristics are depicted in Table 1. The in-hospital
mortality rate was 20% (n= 10). According to the Modified
Duke Criteria, 63% (n= 31) were classified as “definite” and
37% (n= 18) were classified as “possible” endocarditis.
In 82% (n= 40) of the reviewed cases, a causative organism was
identified, whereas culture-negative endocarditis occurred in 18%
(n= 9). Gram-positive organisms were the most common type of
causative organism. Staphylococcus aureus was the commonest
organism cultured (Table 2), occurring in 33% (n= 16) of patients;
44% (n= 7) of those patients had surgery. The case fatality rate was
Table 1. Patient characteristics.
Characteristic n (%), total n= 49
Hospital
Tygerberg Hospital 21 (43)
Red Cross Children’s Hospital 28 (57)
Area of residence
Cape Town 17 (35)
Western Cape (excl. CPT) 29 (59)




Age (months), median (IQR) 81.3 (31.1–21.7)
HIV status, n (%)
Positive 0
Negative 43 (88)
HIV-exposed but negative 6 (12)
Table 2. Organisms and their frequency of occurrence.
Organisms n (%), total n= 40
Staph aureus cloxacillin-sensitive 10 (25)
Strep Viridans (tissue diagnosis, n= 1) 5 (12.5)
Streptococcus pneumoniae 5 (12.5)
Methicillin-resistant Staph aureus 4 (10)
Coagulase-negative Staph aureus 2 (5)
Streptococcus gordoni 2 (5)
Enterococcus species 2 (5)
Group G streptococcus 1 (2.5)
Group A streptococcus 1 (2.5)
Streptococcus agalactia 1 (2.5)
Abiotrophia defectiva (tissue diagnosis) 1 (2.5)
Corynebacterium species 1 (2.5)
Bacillus cereus (tissue diagnosis) 1 (2.5)
Candida species 1 (2.5)
Moraxella catarrhalis 1 (2.5)
Pseudomonas aeruginosa 1 (2.5)
Mycobacterium tuberculosis (tissue diagnosis) 1 (2.5)
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37.5% (n= 6). Out of the 10 in-hospital deaths, 60% (n= 6) were
associated with S. aureus.
Table 3 indicates the underlying cardiac lesions. Unrepaired
CHD occurred in 41% of cases; the most frequently identified
lesion, unrepaired ventricular septal defect, was identified in
20% (n= 10) of cases. RHD was the predisposing condition in
10% (n= 5) of cases. In one patient, endocarditis occurred after
mitral valve replacement for RHD. Repaired or previously oper-
ated CHD occurred in 18% (n= 9), while 31% (n= 15) of patients
had structurally normal hearts. Six per cent (n= 3) of patients had
a central venous catheter and 6% (n= 3) had dental caries.
There were 53 sites involved, with more than one site occurring
in four patients. The list of sites involved is shown in Table 4.
Left-sided valvular endocarditis (47%) occurred more frequently
than right-sided valvular endocarditis (32%).
Embolic phenomena and complications
Congestive heart failure occurred in 41% (n= 20) of patients with a
mortality rate of 14% (n= 3). All patients with multi-organ dys-
function died. Pulmonary embolus occurred in three patients with
a mortality rate of 33%, and cerebral embolus occurred in four
patients with a mortality rate of 25% (Table 5). Three out of 26
patients (11.5%) who had surgery had embolic phenomena prior
to the operation.
Surgery
Surgery was performed in 53% (n= 26) of patients, and medical
therapy alone was used in 45% (n= 22). Information on manage-
ment could not be obtained for one patient who had been trans-
ferred to another facility. Time interval from admission to
surgery was a median of 20 days (interquartile range, 9–47 days).
Twenty-three per cent (n= 6) had tricuspid valve repair, 15%
(n= 4) had mitral valve repair, 11.5% (n= 3) had aortic valve
repair, one had a removal of infected graft and tricuspid valve
repair, and one had both aortic and tricuspid valve repair.
Fifteen per cent (n= 4) had mitral valve replacement with a
mechanical valve, 8% (n= 2) had aortic valve replacement with
a mechanical valve. One patient had aortic valve replaced by
pulmonary autograft (Ross procedure).
Treatment outcomes
Valvular regurgitation and valvular stenosis were grouped together
as valve pathology resulting from endocarditis and classified as
mild, moderate or severe valvular dysfunction. Patients were clas-
sified according to the most severe category of valve dysfunction.
Table 6 is a description of the number of patients who underwent
medical treatment in each classification of valvular dysfunction
prior to and at the completion of treatment. The symmetry test
was not significant (p= 0.08) and the marginal homogeneity test
was borderline significant (p= 0.05), indicating a marginal shift in
the classification of valvular dysfunction pre- and post-treatment.
Six of 14 patients treatedmedically for valvular endocarditis died in
hospital (mortality rate= 43%).
Table 7 is a description of the number of patients who under-
went surgery in each classification of valvular dysfunction prior
to surgery and before discharge. Both the symmetry test and the
marginal homogeneity test are highly significant, thus indicat-
ing a shift in the classification of valvular dysfunction pre- and
post-treatment (p = 0.007 and 0.002). Two of 26 patients man-
aged surgically died postoperatively (post-operative mortality
rate = 7.7%).
Table 3. Underlying conditions.
Underlying cardiac lesion n (%), total n= 49
Unrepaired VSD 10 (20)
PDA 2 (4)
Unrepaired ASD 2 (4)
Unrepaired aortic stenosis 2 (4)
Unrepaired congenitally abnormal mitral valve 2 (4)
Unrepaired DORV 1 (2)
Dilated cardiomyopathy 1 (2)
Repaired VSD 3 (6)
Repaired Tetralogy of Fallot 3 (6)
DORV post-palliative procedure (Glenn shunt) 1 (2)
Tricuspid atresia post-surgical shunt (Grotex) 1 (2)
PDA post-percutaneous device occlusion 1 (2)
RHD unoperated 4 (8)
RHD operated (prosthetic valve) 1 (2)
Structurally normal heart 15 (31)
VSD= ventricular septal defect; PDA= patent ductus arteriosus; ASD= atrial septal defect;
DORV= double outlet right ventricle.
Table 4. Sites of endocardial infection.
Site n (%), total n= 53
Native aortic valve 8 (15.0)
Native mitral valve 16 (30.0)
Native tricuspid valve 12 (23.0)
Native pulmonary valve 5 (9)
Repaired mitral valve 1 (2.0)
Surgical graft 3 (6.0)
Surgical shunt 1 (2.0)
No valvular involvement 7 (13.0)
Table 5. Complications and associated mortality.
Complications/embolic phenomena, n (%)* Mortality rate
Heart failure, 20 (40) 3 (14)
Cerebral embolisation, 4 (8) 1 (25)
Pulmonary embolisation, 3 (6) 1 (33)
Mycotic aneurysm, 4 (8) 1 (25)
Acute renal failure, 5 (10) 1 (20)
Arrhythmia, 1 (2) 0
Glomerulonephritis, 4 (8) 0
Osteomyelitis/septic arthritis, 3 (6) 0
Multiple organ dysfunction, 2 (4) 2 (100)
*Data not available on one patient who was transferred to another facility.
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Overall 6% (n= 3) of patients had severe residual valvular
dysfunction, 24% (n= 12) hadmoderate residual valvular dysfunc-
tion, and 16% (n= 8) had mild residual valvular dysfunction at the
completion of their treatment.
Discussion
Although infective endocarditis is a rare condition in children,
challenges remain in the diagnosis and management of these
patients. We have shown a high in-hospital mortality rate of
20%, and despite a significant reduction of valvular dysfunction
with treatment, >40% of patients were left with some degree of
residual valvular dysfunction – the long-term impact of which is
not apparent in this review. In total, the need for surgery was high,
with more than half of patients undergoing surgical treatment.
The cases of endocarditis in this review were identified
at the two government hospitals in the province but did not
include Christian Barnard Netcare Hospital (a private facility).
Approximately 83% of South Africans use public healthcare facili-
ties, making this a good representation of childhood endocarditis
in the province.10
A reduction in mortality rate in children with endocarditis
from 35% to 20% over the last 40 years at our facility may be
accredited to the introduction of echocardiography in 1982, which
improved diagnostic capabilities, allowing for prompt treatment.11
Echocardiography is central to the diagnosis and management of
endocarditis with a sensitivity of up to 95% in detecting vegetations
in children with “definite” endocarditis.12 The clinical usefulness
of echocardiography is limited however, as not all vegetations
are detected and not all patients have criteria for “definite”
endocarditis.13 The use of Modified Duke Criteria in children
has limitations as well.1,14 In our analysis, a third of the patients
had criteria for “possible” endocarditis. Refinement of the Duke
Criteria and alternate methods of diagnosing endocarditis are
necessary.14 Molecular techniques for the identification of organ-
isms in patients with culture-negative endocarditis have been
developed, but are far better suited for detecting organisms on tis-
sue specimens compared with blood samples.15 Tissue character-
isation cardiac MRI, not yet available at our facility, has been
shown to be an effective method for detecting endocardial inflam-
mation in patients with endocarditis.16 Further studies are required
to validate the utility of this method.
None of the patients in this review were infected with the
human immunodeficiency virus. This finding, supported by the
analysis of childhood endocarditis in Leuven, Belgium,17 suggests
that human immunodeficiency virus infection and an immune-
compromised state does not increase the risk of developing endo-
carditis in children. The hypothesis that a damaged or denuded
endothelium in the presence of bacteraemia is the dominant risk
factor holds true for most cases, but does not account for endocar-
ditis that occurred in patients with structurally normal hearts. It is
interesting to note that this occurred twice as many times in our
analysis compared with that previously described at our facility
(31% versus 14%).11 Increasing use of central venous catheters
in patients in neonatal and paediatric intensive care units may
partly explain this.
Our facility follows the South African Heart Association guide-
lines, which are adapted from the European Society of Cardiology
guidelines, for antibiotic prophylaxis for the prevention of endo-
carditis following dental procedures.18 They recommend restrict-
ing the use of antibiotics to certain high-risk lesions (cyanotic heart
disease and patients with prosthetic material).19 They also emphas-
ised the need for prophylaxis in patients with RHD,19 an important
recommendation given the persistent finding of RHD as a signifi-
cant predisposing condition at our facility over the last few
decades.11 The large number of patients with underlying unre-
paired ventricular septal defects (20%) suggests that these patients
would also likely benefit from antibiotic prophylaxis for dental
procedures.
Staphylococci and streptococci are the most common organisms
isolated in children with endocarditis.7,17 S. aureus endocarditis is a
severe form of the disease accounting for 60% of the in-hospital
deaths. Just over one-third of patients with S. aureus endocarditis
died, and almost half were managed surgically. Its presence neces-
sitates early surgical intervention.20
Residual valvular dysfunction typically results in ventricular
dysfunction, which may contribute to mortality outside of the
treatment period.7 Despite the significant pre- to post-treatment
reduction in valvular dysfunction, a portion of patients had
ongoing valve dysfunction after treatment. Patients who under-
went antibiotic therapy exclusively showed only a marginal
improvement in valvular dysfunction with a high mortality rate
(43%), while patients who had surgery showed a significant
improvement in valvular dysfunction and a far lowermortality rate
(7.7%). Surgery is an important part of the management of these
patients, and one of its life-saving benefits is the ability to decrease
the infectious load.3
The EASE trial clearly showed better short- and long-term out-
comes in terms of embolic phenomena, congestive heart failure,
and death in adult patients with large, left-sided vegetations who
had surgery within 48 hours of diagnosis.6 There was a high rate
of valve replacements in the early surgery group (75%) compared




None Mild Moderate Severe Death Total
None 0 0 1 0 0 1
Mild 0 0 0 0 0 0
Moderate 2 4 3 0 0 9
Severe 3 4 5 2 2 16
Death 0 0 0 0 0 0
Total 6 8 9 2 2 26
Symmetry test p= 0.007 and marginal homogeneity test p= 0.002.




None Mild Moderate Severe Death Total
None 2 0 0 0 1 3
Mild 2 0 0 0 2 4
Moderate 0 0 1 0 0 1
Severe 0 0 2 1 3 6
Death 0 0 0 0 0 0
Total 4 0 3 1 6 14
Symmetry test p= 0.08 and marginal homogeneity test p= 0.05.
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with a slightly lower rate in the conventional management group
(63%).6 The median interval from diagnosis to surgery in the
review from Texas Children’s Hospital was 3 days (interquartile
range, 1.0–7.5 days), and half of the patients had valve replace-
ments.7 The median interval from diagnosis to surgery in our
facility was longer (20 days; interquartile range, 9–47 days), and
27% of patients underwent valve replacement surgery, compared
with 58%who had valve repair surgery. The post-operative mortal-
ity rate was, however, higher in our facility (7.7% versus 2%).7 A
mechanical valve replacement in a child has a life-long risk of
thromboembolism and need for anticoagulation andmonitoring.21
In patients in whom a mechanical valve replacement is inevitable
and the social/geographical factors preclude ongoing surveillance,
decisions are made in the combined cardiothoracic-cardiology
meeting at our facility to treat the patient medically.
Limitations of the study
This was a retrospective study of a relatively small number of
patients. This study focused on short-term outcomes and did
not capture complications or mortality that may have occurred
after the treatment period under review. A prospective registry
would provide better clinical evidence to guide decision-making
with regard to indications for surgery, optimal timing of surgery,
and long-term outcomes of these patients.
Conclusion
Infective endocarditis is a rare, heterogeneous disease. However,
it is associated with a high morbidity and mortality. Confirming
a definite diagnosis was not possible in at least a third of the cases,
highlighting the need for novel techniques for detecting endocar-
dial infection. Early surgery has better outcomes than delayed
surgery, but with higher rates of valve replacement. In order to
attain the lowest overall mortality rate, the lowest post-operative
mortality rate and the highest rate of valve repair, the ideal timing
for surgical intervention appears to be between 3 and 20 days.
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Date: 7-July – 2019 
 
Reviewer: 1 
Comments to the Author 
Willoughby et al performed a retrospective study of pediatric infective endocarditis cases in the Cape Town 
region. They describe a high incidence of valve dysfunction and a better outcome of patients receiving early 
surgery, well having a high need of valve replacement.  The study is well written, and the important issues 
are discussed. As guidelines for IE prophylaxis have changed, data on this topic are of interest to improve 
endocarditis diagnosis, treatment and prevention. 
 
Major comments: 
1) The authors describe underlying CHD in 29 out of 49 patients.  Could you give details on the underlying 
heart diseases in the un-operated and operated group? It is important to know which underlying heart 
diseases are predisposing for infective endocarditis in your setting. 
2) Associated to comment 1, how is the relation between left and right heart endocarditis? Could you give 
details which heart valves were involved and if there was any prosthetic heart valve endocarditis in the 
operated group? 
3) As you mention in the introduction, rheumatic fever is an important underlying disease predisposing for 
endocarditis. It would be important to know what role this disease plays in your patient population. 
4) As known, S. aureus accounts for severe infections. Has there been any relation of S. aureus endocarditis 
with need of surgery or death?  Was there any relation of the other underlying microorganisms with the 
course of the disease? 
5) The current guidelines have restricted the recommendations for antibiotic prophylaxis. Do children in your 
setting get antibiotic prophylaxis? Are the guidelines followed? Is there anything known about entry points 
for endocarditis or risk factors line dental procedure, skin damage etc? 
6) As also mentioned in the discussion, valve replacement is associated with anticoagulant therapy which 
might be not always evident in follow-up in your setting.  Could you give information on the sort of valves 
which were implanted, biological or metal valves and if the potential problems concerning follow-up 
treatment influence the decision making in valve implantation. 
7) Is there any conclusion you take out of this analysis concerning future treatment of these patients in your 
setting? Any lesson to learn out of the data? 
8) I would suggest to keep the introduction short to mention the most important background information / 
statements from literature and move the exact numbers of patients etc. to the discussion section. By that 
results can be compared to these of other studies.   
9) Data are compared to lit 12 from an older endocarditis cohort. Are there other important differences than 
 
 
the incidence of mortality? 
 
Minor comments: 
10) According to which guidelines have the children been treated for endocarditis? 
11) Please mention the proportion of CHD patients in the abstract under the result section. 
12) Could you comment on the follow-up time of patients in the M&M section? 
13) I suggest to replace the word review by analysis in the title. That is less confusion towards the content of 
the study.   
 
Reviewer: 2 
Comments to the Author 
This study retrospectively analyses data of 49 children with infective endocarditis seen at two centres over 
last 5 years. However the details of site, size of vegetations, total embolisations, specific valves affected, 
decision to operate and valve repair vs. replacement has not been described. The conclusions are very 
similar to those of other studies published in the past, including some from developing countries. 
 
Second review: 
Date sent: 31-Jul-2019 
 
Reviewer: 1 
Comments to the Author 
Please use the same  abbreviation for S. aureus throughout the paper ( line 53, page 7). 
 
Reviewer: 2 
Comments to the Author 
The criteria used for making the diagnosis of infective endocarditis must be clearly defined as it has been 
mentioned as AHA criteria at one place and as Duke criteria at another place. 
Size of vegetations and its relation to embolization may also be mentioned if details are available. 
The method used for blood cultures may be mentioned because most developing countries have reported 
much lower percentage of culture positive endocarditis.  
